Medical Library | Shanghai Specialty Hospital Innovation Series
Two Shanghai specialty hospitals are extending the boundaries of respiratory and cardiovascular care. Shanghai Pulmonary Hospital is advancing AI-assisted assessment of pulmonary fibrosis, lung transplantation, and 5G-enabled robotic bronchoscopy. Shanghai Chest Hospital is combining valve intervention, physiological pacing, and pulsed-field ablation for complex structural and rhythm disease.
This Medical Library review summarizes the 2025–2026 progress provided for these two hospitals. It also explains how international patients can prepare records and communicate with pulmonary, transplant, structural-heart, and electrophysiology teams in Shanghai.
1. Shanghai Pulmonary Hospital: AI Staging and Remote Robotic Bronchoscopy
Team: Lung-transplant team and Professor Ni Hao
Focus: Lung transplantation for end-stage lung disease, pulmonary fibrosis, and chest-wall deformity.
Key 2025–2026 milestones
- CTPF AI: The team developed an AI-assisted CTPF system for staging and severity assessment of pulmonary fibrosis in December 2025.
- 5G remote robotics: A 5G remote robotic bronchoscopy procedure was broadcast live in May 2026.
Pulmonary fibrosis is a pattern of lung scarring rather than one single disease. The cause may be idiopathic, autoimmune, occupational, medication-related, post-infectious, or associated with another interstitial lung disease. Staging should combine symptoms, pulmonary-function tests, oxygen needs, high-resolution CT, exercise capacity, blood tests, and sometimes multidisciplinary discussion.
AI can help quantify imaging patterns and estimate disease severity, but it should support rather than replace specialist interpretation. Patients should ask how the CTPF model was trained, which patient populations were included, how it performs across scanners and hospitals, and whether the result changes antifibrotic treatment, monitoring, rehabilitation, or transplant referral.
Remote robotic bronchoscopy may improve access to specialized airway procedures and help connect expertise across locations. The clinical value depends on network stability, image quality, local anesthesia and airway teams, emergency backup, patient selection, and the ability to manage bleeding or pneumothorax. A live demonstration is not the same as evidence that the approach is suitable for every patient.
Our Lung Transplantation at Shanghai Pulmonary Hospital guide provides related background. Patients may also consult our Lung Disease and Critical Care in Shanghai Medical Library article.
Clinical profile: A respiratory program combining AI-based fibrosis assessment, remote procedural connectivity, and advanced lung-transplant evaluation.
2. Lung Transplantation and Chest-Wall Deformity: From Evaluation to Long-Term Support
For patients with end-stage pulmonary fibrosis or another irreversible lung disease, transplant evaluation is a staged process. It may include confirmation of diagnosis, assessment of oxygen and exercise needs, infection screening, nutritional and rehabilitation review, cardiovascular assessment, psychosocial evaluation, and discussion of donor availability and postoperative immunosuppression.
Chest-wall deformity can influence lung mechanics, exercise tolerance, anesthesia risk, and the complexity of thoracic surgery. The appropriate plan depends on the anatomy and the primary disease, not on the presence of deformity alone.
Patients should ask when transplant referral should occur, whether they need pulmonary rehabilitation, what infections or vaccinations must be addressed, how donor allocation works, and what follow-up is required after transplantation.
3. Shanghai Chest Hospital: One-Stop Structural-Heart and Rhythm Intervention
Leads: Professors Li Ruogu and Sun Jiayuan
Focus: Heart-valve disease, pacing for heart failure, and cardiac arrhythmia.
Key 2025–2026 milestones
- Combined valve intervention: A first reported one-stop minimally invasive combined TAVI and TEER procedure was completed in April 2026.
- Physiological pacing: A domestically developed left-bundle-branch pacing delivery system was reported in May 2026.
- Atrial fibrillation: Pulsed-field ablation was reported as a treatment approach in May 2026.
TAVI replaces or treats the aortic valve through a catheter-based approach, while TEER repairs selected mitral-valve regurgitation using an edge-to-edge technique. A combined one-stop procedure may reduce repeated admissions for carefully selected patients with more than one significant valve problem, but it also increases the need for detailed imaging, anesthesia planning, vascular assessment, and post-procedure monitoring.
Left-bundle-branch pacing aims to activate the heart's conduction system more physiologically than conventional right-ventricular pacing in selected patients. The decision depends on conduction disease, ejection fraction, heart-failure symptoms, anatomy, lead stability, and the team's ability to manage complications.
Pulsed-field ablation uses electric fields to create targeted tissue injury around selected arrhythmia pathways. It may reduce certain collateral-tissue risks compared with thermal ablation, but patients still need assessment of pulmonary-vein anatomy, thromboembolic risk, recurrence risk, phrenic-nerve effects, esophageal safety, and the need for repeat treatment.
Our TAVI/TAVR in Shanghai guide provides related background for patients considering catheter-based valve treatment.
Clinical profile: A cardiac program combining one-stop structural intervention, physiological pacing, and next-generation ablation.
4. How to Interpret These Specialty-Hospital Innovations
The two hospitals illustrate different forms of specialized progress:
- Respiratory innovation: using AI and remote robotics to improve assessment and procedural access in complex lung disease.
- Cardiovascular innovation: combining several minimally invasive procedures and newer energy or pacing technologies in selected high-risk patients.
Patients should distinguish between an AI model, a live remote procedure, a clinical trial, a first-in-center operation, and an established standard treatment. The right option depends on imaging, anatomy, organ function, frailty, prior procedures, and the hospital's experience with the specific technique.
5. How CMCS Helps International Patients Communicate with Specialists
For an international patient seeking pulmonary fibrosis, lung-transplant, valve, heart-failure, or arrhythmia care in Shanghai, the first step is to match the clinical question with the right specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a pulmonary consultation, CMCS can help organize high-resolution CT, pulmonary-function tests, oxygen records, six-minute walk results, autoimmune testing, bronchoscopy, biopsy, infection history, and previous antifibrotic treatment. Before a cardiac consultation, CMCS can help organize echocardiography, CT or MRI, coronary angiography, ECG and rhythm monitoring, valve measurements, prior pacing or ablation records, kidney function, and medication history.
CMCS can help patients prepare focused questions such as:
- What does the AI fibrosis assessment add beyond high-resolution CT, pulmonary function, and specialist review?
- Is remote robotic bronchoscopy clinically available for this patient, and what local emergency backup is in place?
- Is the patient ready for lung-transplant evaluation, and what tests or rehabilitation are required first?
- Would a combined TAVI and TEER procedure provide more benefit than staged or surgical treatment?
- Is left-bundle-branch pacing or pulsed-field ablation appropriate for this anatomy and rhythm problem?
- What are the risks, monitoring needs, recurrence or reintervention risks, costs, and alternatives?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient and the treating medical team. CMCS does not independently select an AI tool, bronchoscopy, transplant pathway, valve procedure, pacing system, ablation method, or clinical trial. Its role is to help the patient bring complete information to the right specialist and ensure that evidence, eligibility, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about specialist consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
Shanghai's specialty hospitals are advancing care through AI-based lung-fibrosis assessment, remote airway robotics, lung transplantation, one-stop valve intervention, physiological pacing, and pulsed-field ablation.
For patients, the goal is not to pursue every new device or procedure, but to identify the option that fits the diagnosis, anatomy, organ function, previous treatment, risk profile, and personal goals. This article was prepared from the team and program information provided for editorial use. Research findings, device status, clinical claims, and treatment access should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 Kommentare